Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
OrthoSpineNews
MAY 13, 2025
No serious adverse events (SAEs) were reported, and there was no dose (40X10 6 cells) limiting toxicity at 26-104 weeks. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery.
Let's personalize your content